Loading, please wait....jpg)
.jpg)
CONTINUING PHARMACY EDUCATION
Reversal of Direct Factor-Xa Inhibitors, An Evidence Update
Speaker: Michael P. Gulseth, PharmD, BCPS, FMSHP, FASHP, Anticoagulation Stewardship Director, PGY-2 Thrombosis and Hemostasis Management Residency Program Director, Sanford USD Medical Center, Sioux Falls, SD
ACPE Universal Program ID# 0122-0000-24-016-H01-P (Application-based CE)
1 Contact Hours [0.1 CEU]
Release Date: February 12, 2024
Expiration Date: February 12, 2027
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Application
Target Audience(s)
- Pharmacists
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
There are 2 steps to completing this home-study CE.
Step 1: Watch the video presentation in its entirety.
Step 2: Click on "Take the Test" to complete the post-test and evaluation.
Please Note: A handout is provided. Please print it out and follow along with the audio recording.
Objectives
- Describe current reversal strategies for direct factor-Xa inhibitors, and the theory behind them
- Identify critical real-world evidence that has evolved in this practice space, including strengths and weaknesses of the data
- Compare and contrast the prospective trials than have been conducted with andexanet alfa
- When presented with a patient with a major bleed on a direct factor-Xa inhibitor, determine an appropriate management strategy
Speaker(s)/Author(s)
|
Michael P. Gulseth, PharmD, BCPS, FMSHP, FASHP
|
Activity Number
0122-0000-24-016-H01-P
Release Date:
Feb 12, 2024
Credit Expiration Date:
Feb 12, 2027
CE Hours
1.00